Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the β‑actin control western blotting data shown in Fig. 3D on p. 1893 were very similar to the contol data shown in Fig. 4A on p. 1894; furthermore, the data shown for the MMP‑9 and the INOS protein bands in Fig. 4C were remarkably similar to the data shown for the IL‑1β and IL‑6 proteins, respectively, albeit the backgrounds surrounding the bands were different. Moreover, various of the western blotting data shown in these figures were strikingly similar to data that had already been published in different form in other articles written by (largely) different authors at different research institutes. Owing to the fact that the contentious data in the above article had already been published prior to its submission to Molecular Medicine Reports, and due to the number of apparent duplications of strikingly similar data between Figs. 3 and 4, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 7: 1889‑1895, 2013; DOI: 10.3892/mmr.2013.1444].

OBJECTIVESTo screen and validate differential proteins as novel biomarkers in active Takayasu's arteritis (TAK).METHODSPlasma samples from 40 active, 40 inactive patients, and 40 healthy controls were collected. Protein profiles of plasma were mapped by two-dimensional gel electrophoresis. Differential protein spots were detected and identified by image analysis and mass spectrometry. Plasma concentrations of proteins were measured to validate candidate biomarkers. The area under the receiver operating characteristic (ROC) curve (AUC) of circulating plasma concentrations of candidate biomarkers were calculated to assess diagnostic value.RESULTSWith a total of 1507 matched gel spots, there were 170 differential expression spots between active and inactive TAK, including 139 up-regulated and 31 downregulated. Only 11 proteins could be identified by mass spectrometry. Serum amyloid A(SAA), fibrinogen, complement C4a, complement C3c, complement C4b binding protein(C4bp), recombination acting gene protein 1(RAG1), alpha-1-acid glycoprotein, alpha-1-microglobulin, complement C7, complement factor H related protein-1 were up-regulated in active patients, while serum amyloid P was down-regulated. Active patients had higher circulating levels of RAG1(P<0.001), C4bp (p=0.012) and SAA (p<0.001), compared to inactive patients, while inactive patients had higher levels than controls (RAG1, p=0.011; C4bp, p=0.012; SAA, p=0.005). The composite AUC with SAA, RAG1, and C4bp was 0.94 (95%CI 0.86-0.98) for discriminating activity, larger than 0.71(95% CI 0.60-0.80) for ESR (p=0.0004) or 0.75(95%CI 0.64-0.84) for CRP (p=0.0014), respectively.ONCLUSIONSSome acute-phase and immunology-related proteins may serve as novel biomarkers of TAK. Further study of these proteins may be helpful to elucidate the pathologic mechanism.

Objective:To evaluate the clinical characteristics and treatment of abdominal aortic aneurysm (AAA) with type 2 diabetes.Methods:A retrospective analysis of AAA in January 1991 to Jun 2016,96 cases of patients with type 2 diabetes in study group,surgical approach for matching factors to select 96 patients without type 2 diabetes for control group.Results:Compared with the control group,the preoperative examination of coronary heart disease (P ＜ 0.01) 、hyperlipidemia (P ＜ 0.05) 、hypertension (P ＜ 0.01) 、peripheral arterial disease (P ＜ 0.05) in study group increase statistically significant.LDL-C,LDL-C/HDL-C increased (P ＜ 0.01) statistically significan and HDL-C (P ＜ 0.01) decrease statistically significant in study group.Complications of perioperative respiratory and circulation system (P ＜ 0.05) increase statistically significant in study group.Blood loss,ICU stay at time was no statistical difference.In postoperative follow-up,stent and artificial patency rate was no significant difference,although the number of complications of circulation system than in the control group (11/8) but there was no statistical differences.Conclusion:For the AAA patients with type 2 diabetes should be noted that not only control of blood glucose,but also should control coronary heart disease,high cholesterol,high blood pressure strengthened.Through skilled operative and meticulous perioperative management to reduce complications,and make closed postoperative follow-up.

Background: Severe cerebral ischemia in patients with Takayasu's arteries was caused by occlusion of most supra-aortic arteries. Arterial revascularization is necessary to decrease the incidence of stroke and improve the quality of life but may be complicated with multiple occlusive lesions and inflammation condition of this disease. This study was to assess options and long-term outcomes of surgical and endovascular treatment.Methods: Twenty-nine patients with severe cerebral ischemic symptoms underwent surgical or endovascular treatment from January 1991 to July 2015. Demographic characteristics, surgical and endovascular procedures, and follow-up outcomes were reviewed. Risk factors associated with primary patency of surgical treatment and assisted primary patency of endovascular treatment was identified by Cox regression analyses.Results: There were 29 patients with a median age of 24 (range 9-37 years), 9 in active and 20 in inactive phase. Seventeen patients underwent a variety of bypass procedures. Fourteen endovascular procedures were performed in 12 patients. No death occurred within 30 days after both procedures. Complications within 30 days after bypass included stroke in 1 patient, infection in 2 patients, and heart failure in 1 patient. Nine patients developed brain hyperperfusion after bypass. Transient hemiplegic paralysis occurred in 1 patient during dilation of the carotid artery. During a median follow-up time of 41 months, primary and secondary patency rate of bypass at 1 and 3 years was 93.75% and 100% and 87.5% and 100%, respectively. Assisted primary and secondary patency rate of endovascular treatment at 1 and 3 years was 85.71% and 92.86% and 68.18% and 75.66%, respectively. There was no independent risk factor associated with either primary patency of surgical treatment or assisted primary patency of endovascular treatment. Disease activity was independent risk factor associated with combined rate of primary patency of surgical treatment and assisted primary patency of endovascular treatment (HR: 0.17, 95% CI: 0.03-0.93, P = 0.04).Conclusions: Bypass is the preferred treatment in majority of patients with good long-term patency, even has a higher propensity for postoperative complications. Endovascular treatment should be preserved for short lesions in inappropriate or high-risk surgical patients but needs more reintervention and close monitoring of lesion for better outcomes. Long-term patency of surgical and endovascular treatment is related with disease activity. Combination of surgical or endovascular treatment and medical therapy may improve the efficacy of interventions.

目的:探讨腹主动脉瘤腔内修复术(EVAR)术后单纯Ⅱ型内漏的诊断和治疗方式.方法:回顾性分析2002年1月至2016年4月北京安贞医院血管外科EVAR术后治疗Ⅱ型内漏的发病率、诊断方法、随诊情况以及干预治疗措施.结果:本组EVAR术后发现单纯Ⅱ型内漏36例,发生率10.84％;21例(58.3％)为术后即刻动脉造影显示Ⅱ型内漏存在,另15例(41.7％) EVAR术后即刻动脉造影未发现内漏,随访过程中发现Ⅱ型内漏存在.随访时间3～118个月,平均随访时间17.9个月.Ⅱ型内漏自愈率为47.2％ (17/36).随诊过程中瘤体直径无明显增大27.8％ (10/36).失访率13.9％(5/36).4例Ⅱ型内漏因瘤体直径增加＞10mm给予经动脉途径弹簧圈栓塞术治疗,二次干预治疗率11.1％ (4/36);术中即刻动脉造影Ⅱ型内漏均消失,技术成功率100％.其中2例靶动脉栓塞者随诊12个月无内漏复发,瘤体直径缩小;1例髂内动脉和瘤腔内栓塞,术后复查CTA提示Ⅱ型内漏存在,瘤体直径较栓塞术前缩小3mm,栓塞术后随访21个月Ⅱ型内漏仍存在,瘤体直径无继续增大;1例瘤腔栓塞术后10个月发现Ⅱ型内漏复发且瘤体直径增大10mm,栓塞术后15个月动脉瘤破裂,急诊行腹主动脉瘤切除、腹主动脉至双侧髂总动脉人工血管间置移植术成功,术中确诊为腰动脉来源导致Ⅱ型内漏;目前开腹术后随访6个月患者情况良好.结论:EVAR术后Ⅱ型内漏是比较常见的并发症,在中、远期随访中Ⅱ型内漏的出现甚至导致瘤体直径增加并不少见,甚至可以导致破裂.因此对于EVAR术后严密随访十分重要,尤其对于瘤体直径增大者.应用支撑导管行经动脉途径栓塞术,有助于到达靶动脉开口部位.应用弹簧圈进行靶动脉开口部位确切栓塞可能会降低Ⅱ型内漏的复发率,且安全.其远期疗效有待于更长时间的随访和更多的病例积累.

Lower extremity atherosclerotic occlusive diseases,as one of atherosclerotic occlusive diseases, the incidence of which has been significantly increased. The continuous rise of cardiovascular risk factors such as hypertension, dyslipidemia,diabetes mellitus, smoking and so on are the main causes of the prevalence of arteriosclerosis occlusive disease in China.Therefore, prevention and treatment of arteriosclerosis occlusive disease should be based on the control of risk factors. Pharmacotherapy has a key role. Surgeons should pay more attention to clinical research in order to formulate the guidelines, based on which patients could receive standardized drug treatment, including anti-platelet, lipid-lowering,regulating blood sugar and blood pressure.The purposes are to delay the progress of arteriosclerosis, to improve the ischemic symptoms of the lower limb, to ensure the stent or graft’s patency rate, to reduce the incidence of cardiovascular and cerebrovascular events, and ultimately to improve the survival rate of patients.

Objective This study aimed to compare endovascular treatment and bypass surgery for Takayasu ateritis( TA),to analyze influencing factors and to provide reference data for the treatment options of Takayasu arteritis and prevention of postoperative complications. Methods This is a retrospective review of patients with TA referred to us between 2002 and 2014. We used the American Rheumatism Association standards published in 1990 as diagnostic criteria. Results Total number of patients who received surgery was49,including 44 female cases,accounting for 89. 8%,the average age was( 27. 20 ± 10. 35) years,the bypass surgery was performed for27 cases,endovascular treatment was given to 22 cases( 7 cases received stent placement,15 cases received percutaneous transluminal angioplasty,PTA),61 culprit vessels were treated. The average follow-up period was( 50. 43 ± 42. 708) months( 3-148 months),no deaths occurred. The primary patency rates for 3-month,6-month,1-year,3-year,5-year,10-year were 97. 8%,95. 6%,88. 3%,79. 6%,76. 1% and 57. 1%,respectively. The PTA and stent placement,1-year patency rates were 91. 7% and 68. 6%( P = 0. 045).Only 2 cases had early complications of hemorrhage. Late complications occurred in a total of 13 cases,including 5 cases after endovascular treatment and 8 cases after bypass( P = 0. 002); Cerebral infarction in 1 case,thromboembolism in 6 cases,and restenosis in 5 cases( stent restenosis in 2 cases,3 cases had restenosis after PTA),artificial vascular rejection occurred in 1 case. The overall 1-,3-,5-,10-year no complication rates were 88. 1%,79. 0%,75. 4% and 51. 9%,respectively. The Logistic regression analysis showedthat the immune abnormalities in follow-up period were independent risk factors for postoperative complications( OR: 7. 596,CI: 1. 091-52. 884,P = 0. 041). Conclusion Endovascular treatment was significantly superior to bypass surgery in terms of late complications;no significant difference was found between bypass surgery and endovascular treatment in long-term patency rate. Abnormalities in immune parameters during the period of follow-up may be independent risk factors of postoperative complications,postoperative immunomodulatory therapy may be particularly important. PTA had a better primary patency than stenting.

Objective To investigate the efficacy of hybrid technique treatment for the common femoral artery(CFA)occlusion involving the external iliac artery(EIA).Methods Between May 2008 and April 2013, a retrospective analysis was carried out in 47 patients who underwent CFA endarterectomy,EIA balloon dilatation and stent implantation. Perioperative results and arterial recanalization were analyzed. Results All procedures were performed successfully. The mean amounts of stents were(1.51±0.75)for every patient. Postoperative ankle brachial index(ABI)increased 0.54,and ischemia of lower limbs was improved in all patients. The perioperative complication rate was 17.0%(8/47) and no patient died during perioperative period. The mean follow-up time was(673.6±384.4)days. In-stent occlusion was observed in 4 patients. The primary patency rates were(97.8±2.2)% and(86.3±6.7)% at 12 months and 24 months after operation,respectively,with Kaplan-Meier life-table analysis.Conclusion The perioperative and short term results of hybrid technique treatment for the CFA occlusion involving the EIA are satisfied.

随着人民生活水平的提高和人口老龄化趋势的进程,动脉粥样硬化性病变造成的心脑血管疾病,已经成为严重危害我国人群生命的重大疾病.我们必须控制和预防动脉硬化的发生和发展,抗凝、降糖、降压、降脂各个环节一个都不能忽视.

The development of acute lung injury (ALI) during sepsis almost doubles the mortality rate of patients. The efficacy of current treatment strategies is low as treatment is usually initiated following the onset of symptoms. Inflammation is one of the main mechanisms of autoimmune disorders and is a common feature of sepsis. The suppression of inflammation is therefore an important mechanism for the treatment of sepsis. Sirtuin 1 (Sirt1) has been demonstrated to play a role in the regulation of inflammation. Resveratrol, a potent Sirt1 activator, exhibits anti‑inflammatory properties. However, the role of resveratrol for the treatment of ALI during sepsis is not fully understood. In the present study, the anti‑inflammatory role of Sirt1 in the lipopolysaccharide (LPS)‑induced TC‑1 cell line and its therapeutic role in ALI was investigated in a mouse model of sepsis. The upregulation of matrix metalloproteinase-9, interleukin (IL)‑1β, IL‑6 and inducible nitric oxide synthase was induced by LPS in the mouse model of sepsis and the TC‑1 cell line, and resveratrol suppressed the overexpression of these proinflammatory molecules in a dose‑dependent manner. Resveratrol decreased pulmonary edema in the mouse model of sepsis induced by LPS. In addition, resveratrol improved lung function and reduced pathological alterations in the mouse model of sepsis. Knockdown of Sirt1 by RNA interference resulted in an increased susceptibility of TC‑1 cells to LPS stimulation and diminished the anti‑inflammatory effect of resveratrol. These results demonstrated that resveratrol inhibits LPS‑induced ALI and inflammation via Sirt1, and indicated that Sirt1 is an efficient target for the regulation of LPS‑induced ALI and inflammation. The present study provides insights into the treatment of ALI during sepsis.

静脉血栓栓塞(VTE)包括深静脉血栓形成(DVT)和肺栓塞(PE),严重危害人类健康,甚至危及生命.在VTE的诸多有效治疗手段和方法中,抗凝被指南推荐为基础治疗.低分子肝素(LMWH)和维生素K拮抗剂(VKA)序贯疗法,被多数指南推荐.但序贯疗法存在给药剂量不固定、需要监测INR、与药物食物之间相互作用多、剂量-药效关系不确切和使用方法复杂等问题.

<正>下肢动脉硬化闭塞症的治疗,经过几代人的实践、探索,已经从最初的内膜剥脱术、人工血管或自体大隐静脉旁路开放式手术时代,转化为血管腔内修复时代。目前,随着血管腔内器械的不断更新与改进,临床医师技术日臻完善,下肢动脉硬化闭塞症的腔内治疗呈现出喜人的景象,标志着血管外科已步入以血管腔内诊治技术为主流的新时期。多种通

Objective:The purpose of this study was to compare the outcomes of endovascular therapy to those of aorto-femoral graft bypass for patients with Transatlantic Inter-Society Consensus(TASC Ⅱ) C and D aortoiliac occlusive disease,and to provide evidence for treatment choosing of this disease and experience for other multi-center randomize clinical trials.Methods: From 2005 to 2008,77 patients of TASC C and D aortoiliac occlusive disease underwent surgical and endovascular treatment in Anzhen hospital.35 patients underwent endonvascular therapy(group A) and 42 patients underwent aorto-femoral graft bypass(group B).All clinical,perioperative and follow-up data at average(59.7±18.7) months were obtained.Results: 5 years primary and secondary patency are 68.8% and 78.1% for group A,92.1% and 94.7% for group B.The 5 years survival rate and limb salvage rate are 93.8% and 90.6% of group A,94.7% and 97.3% of group B.Conclusion: TASC C and D lesions can be treated with either endovascular therapy or aortofemoral graft bypass with satisfactory results.Compared with aortofemoral graft bypass,endovascular therapy is associated with decreased long term patency.Aortofemoral bypass should be the first choice for patients without contraindication of open surgery.

Objective:The arm of trial is to study to treat serious lower extremity ischemia by low molecule weight heparin(LMWH)cooperated with sarpogrelate.Methods: We conducted a randomized cohort trial,in which 43 patients(experimental group) were assigned to apply LMWH cooperated with sarpogrelate,40 patients(compared group) were assigned to apply cilostazol cooperated with pancreatic kallikrein.To compare their validity and security between 2 groups.Results: The excellent,productive and invalid ratio of the experimental group are respectively 38.5%(30/78),48.7%(38/78)and 12.8%(10/78).Them of the compared group are respectively 10.1%(7/69),14.5%(10/69)and 75.4%(52/69)(P0.001).There is none of bleeding in two groups.Conclusion: LMWH cooperated with sarpogrelate plays a big role in increasing distance of claudication in FontaineⅡ,eliminating or alleviating rest pain in Fontaine Ⅲ or Ⅳ,promoting to form lateral branch artery,and no in increasing blooding.These give expression to validity and security in treatment of LMWH cooperated with sarpogrelate.

Objective To conclude the diagnosis and treatment experience for acute mesenteric arterial ischemia disease. Methods The clinical data of 28 patients suffered from acute mesenteric ischemia admitted from 2004 to 2013 in Department of Vascular Surgery, Beijing Anzhen Hospital of Capital Medical College were analyzed retrospectively. The data include medication and surgery. Results Among the total 28 patients,11 patients underwent thrombolectomy by Fogarty catheter including 6 patients underwent bowel resection,and the other 17 patients received conservative medication therapy. Two patients(7.1%)died. Conclusion It is urgent to diagnose and treat the acute superior mesenteric ischemic diseases. The medication and surgery are important methods to save patients’ live.

下肢深静脉血栓形成和肺动脉栓塞是血管外科常见疾病,有很高的致残和致死率,也是全科医师经常要处理的一种疾病.本文结合国内外指南和专家共识,介绍如何早期识别和诊断本病,告知诊断的方法、治疗的原则.希望通过本文有助于全科医师的临床工作.

动脉硬化导致心血管疾病和卒中风险增加 人口老龄化已成为世界总体趋势.据估计到2050年,美国65岁以上人口将从现在的4000万增加到8000万.我国老年人口预测到2013年将接近2亿.随着年龄的增长,由动脉硬化导致的心血管疾病和卒中风险都将不断增大. 数据显示,随着年龄的增长,冠心病发病率显著上升.老年冠心病患者发生冠状动脉事件的风险是54岁或更年轻患者的2倍,74岁时男性和女性之间的冠心病和卒中的发病率相似,在这个年龄段冠心病的发生率是卒中的2倍.老年人口不断增长,使预防初发或再发心血管事件成为非常重要的问题.

Objective:To compare postoperative outcomes up to 6 months after endovascular or open repair of AAA.Methods:A randomized,single center clinical trial of 100 patients with eligible AAA who were candidates for both elective endovascular repair and open repair of AAA.Patients were randomized to receive either EVAR(endovascular aneurysm repair) or OR(open repair) of AAA.All-cause deaths,systemic and surgery-related complication were documented.Intraoperative data was also collected.All patients were followed up to 6 months after surgery.Statistical analysis was applied to process collected data.Results:Fifty patients were assigned to EVAR group and 50 to OR group.Thirty-nine patients underwent OR and 61 underwent EVAR eventually.Perioperative mortality was zero for both groups.When followed up to 6 months,all-cause mortality was lower for EVAR(0 % vs.2.6%),but there was no significant difference between the 2 groups.Patients in the EVAR group had reduced median procedure time,blood loss,transfusion requirement,hospital stay,but required much more expensive cost(P0.05).There were no significant differences between the 2 groups in major systemic complication,surgery related complication,secondary therapeutic procedures,but EVAR showed a better outcome during perioperative period.Conclusion:In this report of short-term outcomes after elective AAA repair,perioperative mortality and mobility was low for both procedures.Both EVAR and OR are safe and effective options for AAA.Longer-term outcome data are needed to fully assess the relative merits of the 2 procedures.

The mortality rate was high when the abdominal aortic aneurysm (AAA) ruptured, so early detection and standardized treatment are critical. Compared with traditional open surgery (OR), AAA endovascular aneurysm repair (EVAR) developed rapidly due to the continuous improvement of equipment in recent years. For minimally invasive of EVAR procedure, it has been developed rapidly in some countries and medical centers. But there are still some problems such as indications inconsistent in different centers, ignoring the traditional surgery of the AAA, not strictly regulate the course of treatment, follow-up needs to be strengthened and so on. For the healthy and rapid development of the AAA treatment, it requires a substantial strengthening of the standardized treatment of AAA.

Objective:To investigate the prevention and treatment of perioperative complication during endovascular treatment for iliac artery stenosis or occlusion of arteriosclerosis.Methods:130 iliac arteries lesion in 105 patients received endovascular treatment from June,2006 to June,2010.Results: All procedures were completed successfully except 2 iliac arteries occlusion.Ankle-brachial index(ABI) increased from(0.46 ± 0.28) to(0.79 ± 0.22),there was a significant difference(P0.01).Operative complications rate was 14.2%,including 1 acute myocardium infarction and 1 pulmonary infection before operation,1 iliac artery rupture and 2 contralateral limb arteries embolism during operation,2 brachial arteries thrombosis,2 femoral arteries pseudoaneurysm,4 groin hematomas,2 pulmonary infection and 2 alimentary tract hemorrhage after operation.1 patient died of stress ulcer and alimentary tract hemorrhage,and multiple organs failure,perioperative period mortality was 0.9%.The primary patency was 94.3%,the second patency was 100%.Conclusion: Good results were found in iliac arteriosclerosis patients treated with endovascular technique,local and systemic perioperative complications should be avoided as few as possible.